Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07261644
PHASE3
A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
View on ClinicalTrials.gov
Summary
This study will evaluate the efficacy and safety of 608 in patients with AS.
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis (AS)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2025-11-07
Completion Date
2027-11-18
Last Updated
2025-12-10
Healthy Volunteers
No
Conditions
Interventions
DRUG
608 dose
608 subcutaneous (SC) injection.
DRUG
Placebo
Placebo subcutaneous (SC) injection.
Locations (1)
Site 01
Beijing, Beijing Municipality, China